Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
6 mercaptopurine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 6MP Test Formulation | EXPERIMENTAL | 1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation, for targeted ileal delivery |
| 2. 6MP Reference Formulation | ACTIVE_COMPARATOR | 2 x 50 mg oral tablet, PURINETHOL |
| Name | Type | Description |
|---|---|---|
| Delayed Release 6 mercaptopurine | DRUG | oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose |
| 6 Mercaptopurine | DRUG | Oral Tablet, 2 x 50 mg 6MP Reference, single-dose |
Inclusion Criteria: * 12 male and non-pregnant females, aged 18-50 years, with Crohns Disease (CDAI up to 200), non-smoking. Crohns Disease diagnosis via colonoscopy with biopsy within the past 12 years No CD medications allowed during study other than 5-ASA and symptomatic relief (anti-diarrheals...
6 mercaptopurine is a small molecule being studied for use in Crohn's Disease, a gastrointestinal condition. It is currently in Phase 1 clinical development as an investigational therapy. The drug has been evaluated in a pilot comparative bioavailability study involving patients with Crohn's Disease.
6 mercaptopurine is being developed by Teva Pharmaceutical Industries Limited, which is publicly traded under the ticker TEVA. The company is conducting clinical research on this small molecule for the treatment of Crohn's Disease.
6 mercaptopurine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, with no active trials currently ongoing for this asset.
6 mercaptopurine has one completed clinical trial registered as NCT00774982, titled 'Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients.' This Phase 1 study enrolled 12 participants in Israel and was active-controlled, though not double-blinded.
6 mercaptopurine is being studied in comparison to Purinethol in a clinical trial. The trial NCT00774982 is a comparative bioavailability study of 6 mercaptopurine in a delayed release formulation versus Purinethol, indicating they are distinct formulations being evaluated for Crohn's Disease.